Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06468670
PHASE2

Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

Sponsor: Fujian Cancer Hospital

View on ClinicalTrials.gov

Summary

This study is aimed to evaluate the efficacy and safety of short-course radiotherapy combined with sintilimab in neoadjuvant treatment of stage III, locally advanced esophageal squamous cell carcinoma.

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2024-06-17

Completion Date

2027-06

Last Updated

2024-06-21

Healthy Volunteers

No

Interventions

DRUG

sintilimab,programmed death 1 monoclonal antibody

short-course radiotherapy +sintilimab (200mg, iv, D1, Q3W)